Yahoo Finance 
Global Biotech Partnering Terms and Agreements Report 2022: Comprehensive Access to Available Deals and Contract Documents for 6,500+ Biotech Deals
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Global Biotech Partnering Terms and Agreements 2017-2022" report has been added to ResearchAndMarkets.com's offering.
The Global Biotech Partnering Terms and Agreements 2017 to 2022 report provides comprehensive access to available deals and contract documents for over 6,500 Biotech deals.
These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Biotech agreements announced in the life sciences since 2017.
The report takes the reader through a comprehensive review Biotech deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Biotech partnering deals.
The report presents financial deal term values for Biotech deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Biotech partnering field; both the leading deal values and most active Biotech dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 6,500 online deal records of actual Biotech deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
A comprehensive series of appendices is provided organized by Biotech partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Biotech partnering and dealmaking since 2017.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biotech technologies and products.
Key benefits
Global Biotech Partnering Terms and Agreements 2017 to 2022 provides the reader with the following key benefits:
In-depth understanding of Biotech deal trends since 2017
Access to headline, upfront, milestone and royalty data
Detailed access to actual Biotech contracts entered into by leading biopharma companies
Identify most active Biotech dealmakers since 2017
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Biotech Partnering Terms and Agreements includes:
Trends in Biotech dealmaking in the biopharma industry since 2017
Access to headline, upfront, milestone and royalty data
Access to Biotech contract documents
Leading Biotech deals by value since 2017
Most active Biotech dealmakers since 2017
In Global Biotech Partnering Terms and Agreements 2017 to 2022, the available deals are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Biotech dealmaking
2.1. Introduction
2.2. Biotech partnering over the years
2.3. Most active Biotech dealmakers
2.4. Biotech partnering by deal type
2.5. Biotech partnering by therapy area
2.6. Biotech partnering by technology type
2.7. Deal terms for Biotech partnering
2.7.1 Biotech partnering headline values
2.7.2 Biotech deal upfront payments
2.7.3 Biotech deal milestone payments
2.7.4 Biotech royalty rates
Chapter 3 - Leading Biotech deals
3.1. Introduction
3.2. Top Biotech deals by value
Chapter 4 - Most active Biotech dealmakers
4.1. Introduction
4.2. Most active Biotech dealmakers
4.3. Most active Biotech partnering company profiles
Chapter 5 - Biotech contracts dealmaking directory
5.1. Introduction
5.2. Biotech contracts dealmaking directory
Chapter 6 - Biotech dealmaking by technology type
Appendices
Appendix 1 - Biotech deals by company A-Z
Appendix 2 - Biotech deals by stage of development
Appendix 3 - Biotech deals by deal type
Appendix 4 - Biotech deals by therapy area
Appendix 5 - Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/xlx5tc
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
